the invention belongs to the biotechnology, pharmacy and medicine, and has a wide range of actions.the liquid form of the drug containing \u043d\u0430\u0442\u0438\u0432\u043d\u0443\u044e \u0430\u043c\u0438\u043d\u043e\u043a\u0438\u0441\u043b\u043e\u0442\u043d\u0443\u044e sequence of interferon gamma in human, the size of 145.without methionine at the n end, a \u0438\u043c\u043c\u0443\u043d\u043e\u0441\u0442\u0438\u043c\u0443\u043b\u0438\u0440\u0443\u044e\u0449\u0435\u0439, tumour (\u0430\u043d\u0442\u0438\u043f\u0440\u043e\u043b\u0438\u0444\u0435\u0440\u0430\u0442\u0438\u0432\u043d\u043e\u0439) and antivirus \u0430\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044f\u043c\u0438 and \u0441\u043e\u043b\u044e\u0431\u0438\u043b\u0438\u0437\u0438\u0440\u0443\u044e\u0449\u0438\u0435 agents - 0.5 m arginine (0,2 - 1 mm) and 8 mm l - cysteine (2 to 10 m), a stabilizing additive is biologically inert polymer filler \u0434\u0435\u043a\u0441\u0442\u0440\u0430\u043d with mr 40 \u043a\u0434\u0430 (2% \u0440\u0435\u043e\u043f\u043e\u043b\u0438\u0433\u043b\u044e\u043a\u0438\u043d (0.5% - 5%), 20 mm \u0446\u0438\u0442\u0440\u0430\u0442\u043d\u044b\u0439 buffer (5 to 50 m, ph 5.0 (4)5 - 6.0).the drug does not contain impurities of bacterial \u044d\u043d\u0434\u043e\u0442\u043e\u043a\u0441\u0438\u043d\u043e\u0432, stable in the range of ph from 4.5 to 10, has specific antivirus activity, 2\u2219106 me \/ mg.has the physical and chemical stability during storage for 1.5 years and retains activity when stored for 1.5 years.the protein interferon gamma rights remains in liquid form and is not modified by the drug.in the acute and \u0441\u0443\u0431\u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u043c introduction of medicine experimental animal (mice) almost has no toxic action.in \u0432\u043d\u0443\u0442\u0440\u0438\u043c\u044b\u0448\u0435\u0447\u043d\u043e\u043c introduction of experimental animals (rats) almost has no local - annoying actions.the drug interferon gamma
